371 related articles for article (PubMed ID: 23991729)
21. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
22. Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
Boutros PC; Pintilie M; John T; Starmans MH; Der SD; Shepherd FA; Tsao MS; Jurisica I
J Natl Cancer Inst; 2010 Nov; 102(21):1677-8; author reply 1678-9. PubMed ID: 20921041
[No Abstract] [Full Text] [Related]
23. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
24. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
26. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
27. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
28. Genes and pathology of non-small cell lung carcinoma.
Sakashita S; Sakashita M; Sound Tsao M
Semin Oncol; 2014 Feb; 41(1):28-39. PubMed ID: 24565579
[TBL] [Abstract][Full Text] [Related]
29. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
30. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
J Thorac Oncol; 2018 Mar; 13(3):323-358. PubMed ID: 29396253
[TBL] [Abstract][Full Text] [Related]
31. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Uramoto H; Mitsudomi T
Br J Cancer; 2007 Mar; 96(6):857-63. PubMed ID: 17325698
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
33. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
Gray J; Simon G; Bepler G
Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC).
Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
Lung Cancer; 2010 Oct; 70(1):82-7. PubMed ID: 20064672
[TBL] [Abstract][Full Text] [Related]
36. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.
Slavik T; Asselah F; Fakhruddin N; El Khodary A; Torjman F; Anis E; Quinn M; Khankan A; Kerr KM
Clin Lung Cancer; 2014 Nov; 15(6):398-404. PubMed ID: 25043210
[TBL] [Abstract][Full Text] [Related]
38. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine.
Murgu S; Colt H
Clin Lung Cancer; 2013 Nov; 14(6):609-26. PubMed ID: 24188629
[TBL] [Abstract][Full Text] [Related]
39. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
Arch Pathol Lab Med; 2018 Mar; 142(3):321-346. PubMed ID: 29355391
[TBL] [Abstract][Full Text] [Related]
40. 16th World Conference on Lung Cancer.
Landman A
Lancet Oncol; 2015 Oct; 16(13):1290. PubMed ID: 26387750
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
